Andrew Spaventa filed an initial statement of beneficial ownership with the SEC on October 29, 2026, disclosing his securities holdings in Aspen Neuroscience, Inc. (NASDAQ:ASPE) upon becoming a director of the company.

Key Highlights

  • Direct common stock: Spaventa reported direct beneficial ownership of 7,747 shares of common stock.
  • Indirect common stock: An additional 49,914 shares of common stock are held indirectly through The Andrew K. Spaventa Living Trust Dated April 9, 2014.
  • Preferred stock conversions: Spaventa indirectly holds derivative securities convertible into 70,194 shares (via Series Seed Convertible Preferred Stock) and 180,221 shares (via Series C Convertible Preferred Stock), both held through Axon Holdings, LLC entities of which he is a managing partner.
  • Stock options: Two direct stock options are disclosed, one exercisable through June 15, 2032 covering 29,345 shares of common stock at $7.71 per share, and one expiring November 25, 2035 covering 19,226 shares at $5.74 per share.
  • Amended vesting schedule: According to the filing, in September 2026 the vesting schedule for the November 2025 option was amended so that unvested shares as of September 25, 2026 vest in equal monthly installments through November 20, 2031, subject to continuous service.

Spaventa's Initial Ownership Disclosure at Aspen Neuroscience

Andrew Spaventa submitted a Form 3 to the SEC dated October 29, 2026, reporting his initial beneficial ownership of securities in Aspen Neuroscience, Inc., listed on NASDAQ:ASPE. The filing was triggered by his becoming a director of the issuer, as indicated in the relationship checkbox on the form. The filing was signed by Jeffrey L. Boerneke as attorney-in-fact under a Power of Attorney (Exhibit 24).

According to the filing, Spaventa directly owns 7,747 shares of common stock. An additional 49,914 shares are held indirectly through The Andrew K. Spaventa Living Trust Dated April 9, 2014. On the derivative securities side, Spaventa indirectly holds Series Seed Convertible Preferred Stock through Axon Holdings, LLC Series XIII - Aspen Seed, convertible into 70,194 shares of common stock, and Series C Convertible Preferred Stock through Axon Holdings, LLC Series XXI - Aspen C, convertible into 180,221 shares. The filing notes that in connection with the completion of the issuer's initial public offering, each share of preferred stock will automatically convert on a 1-for-9.8821 basis into common stock for no additional consideration, with no expiration date on the securities.

Two stock options are also reported. The first, granted June 16, 2022, covers 29,345 shares at an exercise price of $7.71 and is described in the filing as "fully vested and exercisable," expiring June 15, 2032. The second, granted November 26, 2025, covers 19,226 shares at $5.74 per share, expiring November 25, 2035. The filing discloses that the vesting schedule for this second option was amended in September 2026, with unvested shares as of September 25, 2026 now vesting in equal monthly installments through November 20, 2031, subject to Spaventa's continuous service through each vesting date.

What Was Disclosed

Andrew Spaventa filed an initial beneficial ownership statement as a newly identified director of Aspen Neuroscience, Inc., disclosing direct and indirect holdings across common stock, convertible preferred stock, and two stock options with exercise prices of $7.71 and $5.74.